Yet the response from the health community is non-commensurate. In our 2017 overview of the burden from MCCs, presented at a World Economic Forum event in September 2017 alongside the United Nations General Assembly, we concluded that despite MCCs being so prevalent, there is a dearth of information on their prevalence, clustering, cost and patient burden. 3A 2018 systematic review published in BMJ Global Health by Sum et al aimed to quantify out-of-pocket expenditure (OOPE) on medicines in patients with MCCs. 4 Using the context of the findings from Sum et al, we argue why MCCs warrant specific focus by the health community.